An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy
Diabetes is the 4th most common disease affecting the world’s population. It is accompanied by many complications that deteriorate the quality of life. Painful diabetic neuropathy (PDN) is one of the debilitating consequences of diabetes that effects one-third of diabetic patients. Unfortunately, th...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2022/9989272 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568447597281280 |
|---|---|
| author | Zunaira Qureshi Murtaza Najabat Ali Minahil Khalid |
| author_facet | Zunaira Qureshi Murtaza Najabat Ali Minahil Khalid |
| author_sort | Zunaira Qureshi |
| collection | DOAJ |
| description | Diabetes is the 4th most common disease affecting the world’s population. It is accompanied by many complications that deteriorate the quality of life. Painful diabetic neuropathy (PDN) is one of the debilitating consequences of diabetes that effects one-third of diabetic patients. Unfortunately, there is no internationally recommended drug that directly hinders the pathological mechanisms that result in painful diabetic neuropathy. Clinical studies have shown that anticonvulsant and antidepressant therapies have proven fruitful in management of pain associated with PDN. Currently, the FDA approved medications for painful diabetic neuropathies include duloxetine, pregabalin, tapentadol extended release, and capsaicin (for foot PDN only). The FDA has also approved the use of spinal cord stimulation system for the treatment of diabetic neuropathy pain. The drugs recommended by other regulatory bodies include gabapentin, amitriptyline, dextromethorphan, tramadol, venlafaxine, sodium valproate, and 5 % lidocaine patch. These drugs are only partially effective and have adverse effects associated with their use. Treating painful symptoms in diabetic patient can be frustrating not only for the patients but also for health care workers, so additional clinical trials for novel and conventional treatments are required to devise more effective treatment for PDN with minimal side effects. This review gives an insight on the pathways involved in the pathogenesis of PDN and the potential pharmacotherapeutic agents. This will be followed by an overview on the FDA-approved drugs for PDN and commercially available topical analgesic and their effects on painful diabetic neuropathies. |
| format | Article |
| id | doaj-art-9d7d6a062aa244a6a8421d36f225d876 |
| institution | Kabale University |
| issn | 2314-6753 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-9d7d6a062aa244a6a8421d36f225d8762025-02-03T00:59:08ZengWileyJournal of Diabetes Research2314-67532022-01-01202210.1155/2022/9989272An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic NeuropathyZunaira Qureshi0Murtaza Najabat Ali1Minahil Khalid2Department of Biomedical Engineering and SciencesDepartment of Biomedical Engineering and SciencesDepartment of Biomedical Engineering and SciencesDiabetes is the 4th most common disease affecting the world’s population. It is accompanied by many complications that deteriorate the quality of life. Painful diabetic neuropathy (PDN) is one of the debilitating consequences of diabetes that effects one-third of diabetic patients. Unfortunately, there is no internationally recommended drug that directly hinders the pathological mechanisms that result in painful diabetic neuropathy. Clinical studies have shown that anticonvulsant and antidepressant therapies have proven fruitful in management of pain associated with PDN. Currently, the FDA approved medications for painful diabetic neuropathies include duloxetine, pregabalin, tapentadol extended release, and capsaicin (for foot PDN only). The FDA has also approved the use of spinal cord stimulation system for the treatment of diabetic neuropathy pain. The drugs recommended by other regulatory bodies include gabapentin, amitriptyline, dextromethorphan, tramadol, venlafaxine, sodium valproate, and 5 % lidocaine patch. These drugs are only partially effective and have adverse effects associated with their use. Treating painful symptoms in diabetic patient can be frustrating not only for the patients but also for health care workers, so additional clinical trials for novel and conventional treatments are required to devise more effective treatment for PDN with minimal side effects. This review gives an insight on the pathways involved in the pathogenesis of PDN and the potential pharmacotherapeutic agents. This will be followed by an overview on the FDA-approved drugs for PDN and commercially available topical analgesic and their effects on painful diabetic neuropathies.http://dx.doi.org/10.1155/2022/9989272 |
| spellingShingle | Zunaira Qureshi Murtaza Najabat Ali Minahil Khalid An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy Journal of Diabetes Research |
| title | An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy |
| title_full | An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy |
| title_fullStr | An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy |
| title_full_unstemmed | An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy |
| title_short | An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy |
| title_sort | insight into potential pharmacotherapeutic agents for painful diabetic neuropathy |
| url | http://dx.doi.org/10.1155/2022/9989272 |
| work_keys_str_mv | AT zunairaqureshi aninsightintopotentialpharmacotherapeuticagentsforpainfuldiabeticneuropathy AT murtazanajabatali aninsightintopotentialpharmacotherapeuticagentsforpainfuldiabeticneuropathy AT minahilkhalid aninsightintopotentialpharmacotherapeuticagentsforpainfuldiabeticneuropathy AT zunairaqureshi insightintopotentialpharmacotherapeuticagentsforpainfuldiabeticneuropathy AT murtazanajabatali insightintopotentialpharmacotherapeuticagentsforpainfuldiabeticneuropathy AT minahilkhalid insightintopotentialpharmacotherapeuticagentsforpainfuldiabeticneuropathy |